

Jan Van Riggelen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11257097/publications.pdf>

Version: 2024-02-01

19
papers

1,794
citations

567281

15
h-index

794594

19
g-index

19
all docs

19
docs citations

19
times ranked

3703
citing authors

#	ARTICLE	IF	CITATIONS
1	MYC as a regulator of ribosome biogenesis and protein synthesis. <i>Nature Reviews Cancer</i> , 2010, 10, 301-309.	28.4	751
2	Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 13028-13033.	7.1	370
3	Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 16266-16271.	7.1	144
4	MYC – Master Regulator of the Cancer Epigenome and Transcriptome. <i>Genes</i> , 2017, 8, 142.	2.4	107
5	The interaction between Myc and Miz1 is required to antagonize TGF β ² -dependent autocrine signaling during lymphoma formation and maintenance. <i>Genes and Development</i> , 2010, 24, 1281-1294.	5.9	97
6	Indispensable role of the Ubiquitin-fold modifier 1-specific E3 ligase in maintaining intestinal homeostasis and controlling gut inflammation. <i>Cell Discovery</i> , 2019, 5, 7.	6.7	45
7	DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt's lymphoma. <i>Oncotarget</i> , 2017, 8, 76898-76920.	1.8	44
8	Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 17432-17437.	7.1	38
9	Loss of Net as Repressor Leads to Constitutive Increased c-fos Transcription in Cervical Cancer Cells. <i>Journal of Biological Chemistry</i> , 2005, 280, 3286-3294.	3.4	30
10	Disturbance of Tumor Necrosis Factor Alpha-Mediated Beta Interferon Signaling in Cervical Carcinoma Cells. <i>Journal of Virology</i> , 2002, 76, 280-291.	3.4	27
11	MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL. <i>Epigenetics and Chromatin</i> , 2019, 12, 41.	3.9	23
12	Myc and a Cdk2 senescence switch. <i>Nature Cell Biology</i> , 2010, 12, 7-9.	10.3	21
13	FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome. <i>Leukemia</i> , 2018, 32, 2363-2373.	7.2	20
14	Glycine decarboxylase is a transcriptional target of MYCN required for neuroblastoma cell proliferation and tumorigenicity. <i>Oncogene</i> , 2019, 38, 7504-7520.	5.9	20
15	p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia. <i>Oncotarget</i> , 2015, 6, 3563-3577.	1.8	20
16	Targeting the MYC Oncogene in Burkitt Lymphoma through HSP90 Inhibition. <i>Cancers</i> , 2018, 10, 448.	3.7	14
17	Ectopic Expression of Nonliganded Retinoic Acid Receptor β Abrogates AP-1 Activity by Selective Degradation of c-Jun in Cervical Carcinoma Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 45408-45416.	3.4	10
18	Expression regulation and function of PD-1 and PD-L1 in T lymphoma cells. <i>Cellular Immunology</i> , 2021, 366, 104397.	3.0	7

#	ARTICLE	IF	CITATIONS
19	TGFÎ ² -dependent gene expression shows that senescence correlates with abortive differentiation along several lineages in Myc-induced lymphomas. <i>Cell Cycle</i> , 2010, 9, 4622-4626.	2.6	6